Single injection treatment of meningococcal meningitis. 1. Long-acting penicillin. 1979

J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood

A single injection of a long-acting preparation of penicillin (Triplopen) was compared with a five-day course of crystalline and procaine penicillin in the treatment of meningococcal meningitis. The clinical response of patients treated with Triplopen was very similar to that of patients treated with crystalline penicillin and much more convenient to administer. However, four patients treated with Triplopen had a positive CSF culture 48 or 72 hours after their injection. One injection of Triplopen cannot, therefore, be recommended as an entirely safe form of treatment for meningococcal meningitis unless patients can be carefully followed.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008585 Meningitis, Meningococcal A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8) Meningitis, Neisseria,Neisseria Meningitis,Meningitis, Meningococcal, Serogroup A,Meningitis, Meningococcal, Serogroup B,Meningitis, Meningococcal, Serogroup C,Meningitis, Meningococcal, Serogroup W-135,Meningitis, Meningococcal, Serogroup W135,Meningitis, Meningococcal, Serogroup Y,Meningitis, Meningococcic,Meningococcal Meningitis, Serogroup A,Meningococcal Meningitis, Serogroup B,Meningococcal Meningitis, Serogroup C,Meningococcal Meningitis, Serogroup W-135,Meningococcal Meningitis, Serogroup W135,Meningococcal Meningitis, Serogroup Y,Serogroup A Meningococcal Meningitis,Serogroup B Meningococcal Meningitis,Serogroup C Meningococcal Meningitis,Serogroup W-135, Meningococcal Meningitis,Serogroup W135, Meningococcal Meningitis,Serogroup Y, Meningococcal Meningitis,Meningococcal Meningitis,Meningococcal Meningitis, Serogroup W 135,Neisseria Meningitides,Serogroup W 135, Meningococcal Meningitis
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
January 1979, Transactions of the Royal Society of Tropical Medicine and Hygiene,
J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
January 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene,
J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
February 1978, Vrachebnoe delo,
J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
September 1998, Lancet (London, England),
J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
January 1987, Pediatrics,
J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
January 1945, British medical journal,
J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
December 1947, Wiener medizinische Wochenschrift (1946),
J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
September 1984, Medicina clinica,
J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
January 1969, Scandinavian journal of infectious diseases,
J T Macfarlane, and F I Anjorin, and P G Cleland, and M Hassan-King, and S Tor-Agbidye, and S S Wali, and W R Weir, and H C Whittle, and H N Yahaya, and B M Greenwood
December 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!